Bayer Remains Bullish On Asia After Solid Year
This article was originally published in PharmAsia News
Executive Summary
Regional uptake of its innovative medicines drove Bayer to another year of solid growth in the Asia-Pacific region, where the German group sees continued prospects given demographic patterns and unmet needs.
You may also be interested in...
Asia-Pacific Shapes Innovation Push Amid ‘Tsunami’ Of Aging
Asia-Pacific's growing aging population is expected to bring with it multiple challenges including a higher burden of non-communicable diseases. But health innovations, including crowd-sourced initiatives, could play a key role in improving the "health span" of the silver generation, experts at a recent conference in Singapore suggested.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.